Docket Number 47508.701

Application Number 09/770,602

Applicant Agrawal

Filing Date January 26, 2001

Group Art Unit

Sheet OF 2 1

		U.	S. Patent Docume	nts	•	
EXAMINER MITTIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
4.3	5,149,798	09/22/92	Agrawal et al.	536	. 27	
UW	5,886,165	03/23/99	Kandimalla et al.	536	23.1	

		Forei	gn Patent Docur	nents			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
02	WO 98/00564	01/08/98	PCT	C12Q	1/68	YES	NO
(40	WO 98/49288	11/05/98	PCT	C12N	15/11		·· ·-

\leftarrow			Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
$\backslash \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \!$	2	A1	Khorana et al. (1972) "Studies on Polynucleotides," J. Molec. Biol. 72:209
		A2	Reese (1978) "The Chemical Synthesis of Oligo- and Poly-Nucleotides By The Phosporotriester Approach," Tetrahedron 34:3143-3179
V		А3	Beaucage et al. (1981) "Deoxynucleoside Phosphoramidites – A New Class of Key Intermediates for Deoxypolynucleotide Synthesis," <i>Tetrahedron Lett.</i> 22:1859-1862
	L	A4	Connolly et al. (1984) "Synthesis and Characterization of an Octanucleotide Containing the <i>Eco</i> RI Recognition Sequence With A Phosphorothioate Group At The Cleavage Site," Biochemistry 23:3443
	L	A 5	Agrawal et al. (1987) "Oligodeoxynucleotise Methylphosphonates: Synthesis and Enzymic Degradation," Tetrahedron Lett. 28(31):3539-3542
		A6	Jager et al. (1988) Oligonucleotide <i>N</i> -Alkylphosphoroamidates: Synthesis and Binding to Polynucleotides," Biochemistry 27:7237
		A7	Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoroamidates and Phosporothioates As Inhibitors of Human Immunodeficiency Virus, <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083
		A8	Zon et al. (1991) "Phosphorothioate Oligonculeotides" Oligonucleotides and Analogues: A Practical Approach pp. 87-108
		A10	Kuramoto et al. (1992) "Oligonucleotide Sequences Required For Natural Killer Cell Activation," <i>Jpn. J. Cancer Res.</i> 83:1128-1131
ļ	L	A11	Crooke (ed) (1993) Antisense Research and Applications CRC Press, Boca Raton, Florida
	L	A12	McIntyre et al. (1993) "A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-kB p65 Causes Sequence-Specific Immune Stimulation," <i>Antisense Res. Dev.</i> 3:309-322
		A13	Zon (1993) "Protocols for Oliognucleotides and Analogs," Methods in Molecular Biology Vol. 20, pp. 165-189
		A14	Agrawal et al. (1995) "Modified Oligonucleotides as Therapeutic and Diagnostic Agents," Curr. Opin. Biotechnol. 6:12-19
	\perp	A15	Crooke (1998) "An Overview of Progress in Antisense Therapeutics," Antisense Nucleic Acid Drug Dev. 8:115-122
		A16	Krieg et al. (1995) "CpG Motifs In Bacterial DNA Trigger Direct B-Cell Activation," Nature 371:546-549
		A17	Liang et al. (1996) "Activation of Human B Cells By Phosphorothioate Oligodeoxynucleotides," <i>J. Clin. Invest.</i> 98:1119-1129
		A18	Zhao et al. (1996) "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," <i>Biochem. Pharm.</i> 51:173-182
	T	A19	Krieg (1998) "Leukocyte Stimulation by Oligodeoxynucleotides," Appl. Antisense Oligo. Tech. 24:431-447
		A20	McCluskie et al. (1998) "Cutting Edge: CpG DNA is A Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice," <i>J. Immunol.</i> 161:4463-4466
		A21	Moldoveanu et al. (1998) "CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Virus," <i>Vaccine</i> 16:1216-1224

EXAMINER\	DATE CONSIDERED /
	1 0 0
Jae 7	1/8/03
EVANALED.	
EXAIVINGA: Initial if citation is considered, whether or not citati	on is in conformance with MPEP § 609: Draw Line through citation
if not conformance and not considered. Include copy with next con	nmunication to applicant.
	mile in the complete of the co

BOSTON 1246503v1

NFORMATION DISCLOSURE AVAILABLE (1997) Applicant O9/770,602	<u> </u>	<u></u>				<u> </u>	
Filing Date Sheet 2 OF 2 January 26, 2001 Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," Blochmica et Biophysica Acts 1489:55-68 Acts (Numar et al. (1993) "Properties of Mixed Backbone Oligonucleotides Containing 3"-O-Methyl Ribonucleosides," Blocy & Mac Chem. 24:51:52:520 Acts (1993) "Sile of Chemical Modifications in CpG Containing as O-Methyl Ribonucleosides," Blocy & Mac Chem. 14:10:31:52:520 Acts (1993) "Sile of Chemical Modifications in CpG Containing Prosphorothicate Oligodeoxynucleotide Modulates its Immunostimulatory Activity," Bloory & Med. Chem. Lett. 3:3453-3458 Acts (1993) "Sile of Chemical Modifications in CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bloory & Med. Chem. Lett. 10:1051-1054 Acts (1993) "Sile of Chemical Modifications in CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bloory & Med. Chem. Lett. 10:1051-1054	PE				CLIDE	Docket Number 47508.701	
Filing Date Sheet 2 OF 2 January 26, 2001 Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," Biochimica et Biophysica Acts 1489:55-68 Kumar et al. (1999) "Properties of Mixed Backbone Oligonucleotides Containing 3"-O-Methyl Ribonucleosides," Biocy & Mac Chem. 24:51:52:200 A24 Picture 1, (1999) "Sile of Themical Modifications in CpG Containing 1"-O-Methyl Ribonucleosides," Biocy & Medical Medical Chem. 24:51:52:52:52:52:52:52:52:52:52:52:52:52:52:	1 4	2001	IN AN APPL	JISCLO	NAVAII	ABLE COPY Appli	
Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides." Biochimica et Biophysica Acts 1489:53-68 May Med Chem. 92:515-2820 A24 Pistetky et al. (1999) "Influence of Backbone Chemistry on Immune Activation by Synthetic Oligonucleotides." Biochem. Pharms. 58:1981-1988 A25 Zhao et al. (1999) "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodecoxynucleotide Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 A26 Med. Active Statement of Active Statement of Single Deoxynucleoside, Bioorg. & Med. Chem. Lett. 10:1051-1054 A27 Deox et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodecoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054		Ö (Us				/ \gia	
Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," Blochtmica et Biophysica Acts 1495/53-88 Agra Sluma et al. (1999) "Repeties of Mixed Backbone Oligonucleotides Containing 3"-O-Methyl Ribonucleosides," Bloog, & Med. Chem. 9:2515-2520 Agra Bloog, & Med. Chem. 1999, "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates Its Immunostimulatory Activity," Bloog, & Med. Chem. Lett. 9:3453-3458 Agra Calconomic State of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulated by Modification of a Single Deoxynucleoside," Bloog. & Med. Chem. Lett. 10:1051-1054 BYAMIGEN EXAMIGEN EXAMIGEN DATE CONSINEERD EXAMIGEN DATE CONSINEERD EXAMIGEN DATE CONSINEERD LATE CONSINEERD	TAR	Sheet	2	OF	2	<u> </u>	Group Art Unit
A23 Biochimica et Biophysica Acts 1489-53-68 Kumar et al. (1999) "Foperhies of Mixed Backbone Oligonucleotides Containing 3"-O-Methyl Ribonucleosides," Biocry, & Med. Chem. 9:2515:2520	يخ						
Pisetsky et al. (1999) "Influence of Backbone Chemistry on Immune Activation by Synthetic Oligonucleotides," Biochem. Pharm. 58:1981-1988 Zhao et al. (1999) "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates Its Immunostimulatory Activity," Biocrag. & Med. Chem. Lett. 93:453-3458 Zhao et al. (2000) "Immunostimulatory Activity," Biocrag. & Med. Chem. Lett. 10:1051-1054 A26 Modulated by Modification of a Single Deoxynucleoside," Biocrag. & Med. Chem. Lett. 10:1051-1054 Modulated by Modification of a Single Deoxynucleoside," Biocrag. & Med. Chem. Lett. 10:1051-1054 EXAMIGER: DATE CONSIDERED.		A22	Biochimica et Bi	ophysica Act	s 1489:53-68		-
A26 A26	Ц	VI	Bioorg. & Med.	Chem. 9:2515	5:2520		
Modulates its immunostimulatory Activity," Bioorg. & Med. Chem. Lett. 9:353-458 Zha et al. (2000) "immunostimulatory Activity of CpC Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054 Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054	-		Biochem. Pharn Zhao et al. (199	n. 58:1981-19 9) "Site of Ch	988 jemical Modification	ons in CpG Containning Phosphoroth	ioate Oligodeoxynucleotide
Modulated by Modification of a Single Deoxynucleoside," Bioorg. & Med. Chem. Lett. 10:1051-1054	-		Modulates Its In	ımunostimula	atory Activity," Bio	org. & Med. Chem. Lett. 9:3453-3458	
EXAMINER DATE CONSIDERED		A26	Modulated by M	odification of	a Single Deoxyni	ucleoside," <i>Bioorg. & Med. Chem. Let</i>	t. 10:1051-1054
EXAM(VER) DATE CONSIDERED 1/2/03	-					160	
EXAMINER 2 DATE CONSIDERED 1/2/2/23							
EXAMINER DATE CONSIDERED	-						
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED	-				·		
EXAMINER DATE CONSIDERED	-				. —		
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED	-						
EXAMINER DATE CONSIDERED	E						•
EXAMINER DATE CONSIDERED	_				···		
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED	\vdash						· · · · · · · · · · · · · · · · · · ·
EXAMINER DATE CONSIDERED	-						
EXAMINER DATE CONSIDERED							<u> </u>
EXAMINER DATE CONSIDERED	<u> </u>						
EXAMINER DATE CONSIDERED	\vdash			_		· · · · · · · · · · · · · · · · · · ·	
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED	ļ						
EXAMINER DATE CONSIDERED	-						<u> </u>
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED	-						
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED	-					·	
EXAMINER DATE CONSIDERED							
EXAMINER DATE CONSIDERED / 2 / 2 / 2							
EXAMINER DATE CONSIDERED / 2 / 2 / 2							
EXAMINER DATE CONSIDERED 1/8/03							
1/8/03	E	XAMINER	$\overline{}$			DATE CONSIDERED ,	7
			1-6			1 / 3	2/02

EXAMINER: Initial of citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.